Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 13, 2016 12:21 AM ET


Company Overview of Thrombolytic Science International, LLC

Company Overview

Thrombolytic Science International, LLC engages in the development of a thrombolytic product. It provides M5, a thrombolytic drug that is used for percutaneous coronary intervention and ischemic stroke. The company was incorporated in 2004 and is based in Cambridge, Massachusetts.

763D Concord Avenue

Cambridge, MA 02138

United States

Founded in 2004





Key Executives for Thrombolytic Science International, LLC

Co-Founder, Chief Executive Officer and President
Co-Founder and Scientific Director
Compensation as of Fiscal Year 2015.

Thrombolytic Science International, LLC Key Developments

Thrombolytic Science International, LLC Presents at Redefining Early Stage Investments (RESI) Conference 2016, Jan-12-2016

Thrombolytic Science International, LLC Presents at Redefining Early Stage Investments (RESI) Conference 2016, Jan-12-2016 . Venue: Marine's Memorial Club & Hotel, 609 Sutter St, San Francisco, CA 94102, United States.

Thrombolytic Science, LLC enters into agreement with National Institutes of Health to Test a Novel Thrombolytic Regimen for the Treatment of Acute Ischemic Stroke in Phase IIa Clinical Trial

Thrombolytic Science, LLC (TSI) announced that is has entered into an agreement with the National Institutes of Health (NIH). Under a Cooperative Research and Development Agreement (CRADA) with the National Institute of Neurological Disorders and Stroke (NINDS), and upon receipt of an IND from the FDA, TSI will work with leading researchers at the NINDS /Intramural Stroke Program to test the safety of dual thrombolytic therapy using tissue plasminogen activator and an improved version of prourokinase (HisproUK) in patients suffering from acute ischemic stroke (AIS). TSI will provide the study drug while NINDS will conduct a phase IIa trial. The multicenter trial will be performed in a population of AIS patients recruited by the NIH intramural stroke program, using a combined clinical and MRI-guided approach to patient selection.

Similar Private Companies By Industry

Company Name Region
Montigen Pharmaceuticals Inc. United States
PharmTak Inc. United States
Somerset Pharmaceuticals, Inc. United States
Neuera Pharmaceuticals, Inc. United States
Highland Pharmaceuticals, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Thrombolytic Science International, LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at